FUTURE IWG SYMPOSIA

News in the pathogenesis and treatment of glomerular disease
IWG (Immunonephrology Working Group)
IWG

Part I - Complement mediated diseases: pathogenesis, new entities, upcoming treatments, how to handle expensive drugs
Complement activation in immune-mediated glomerular disease
Mohamed R. Daha, Leiden, The Netherlands
Complement staining in kidney biopsy (C3, C4, C5b-9)
Pablo Cannata-Ortiz, Madrid, Spain
Complement in ANCA-associated Vasculitis - new therapeutic target?
Annette Bruchfeld, Stockholm, Sweden
Complement activation in IgA nephropathy, membranous nephropathy and FSGS
Yasar Caliskan, Istanbul, Turkey
Targeting complement in atypical hemolytic uremic syndrome and C3 glomerulopathy
Giuseppe Remuzzi, Bergamo, Italy

Part II - Individualized (personalized) treatment of glomerular disease – is it already possible?
Personalized immunomonitoring and treatment in lupus nephritis
Hans-Joachim Anders, Munich, Germany
Personalized monitoring and treatment in membranous nephropathy
Jack F.M. Wetzels, Nijmegen, The Netherlands
Personalized approach to IgA nephropathy, is supportive care the response for most patients?
Renato Monteiro, Paris, France
Personalized treatment in ANCA-associated vasculitis
Mårten Segelmark, Linköping, Sweden
Hematuria in glomerular disease - is it important for the outcome of the patients?
Jesus Egido, Madrid, Spain

- See more at: http://www.era-edta2017.org/en-US/preliminary-scientific-programme-1#sthash.S273ZyBf.dpuf
News in the pathogenesis and treatment of glomerular disease
IWG (Immunonephrology Working Group)
IWG

Part I - Complement mediated diseases: pathogenesis, new entities, upcoming treatments, how to handle expensive drugs
Complement activation in immune-mediated glomerular disease
Mohamed R. Daha, Leiden, The Netherlands
Complement staining in kidney biopsy (C3, C4, C5b-9)
Pablo Cannata-Ortiz, Madrid, Spain
Complement in ANCA-associated Vasculitis - new therapeutic target?
Annette Bruchfeld, Stockholm, Sweden
Complement activation in IgA nephropathy, membranous nephropathy and FSGS
Yasar Caliskan, Istanbul, Turkey
Targeting complement in atypical hemolytic uremic syndrome and C3 glomerulopathy
Giuseppe Remuzzi, Bergamo, Italy

Part II - Individualized (personalized) treatment of glomerular disease – is it already possible?
Personalized immunomonitoring and treatment in lupus nephritis
Hans-Joachim Anders, Munich, Germany
Personalized monitoring and treatment in membranous nephropathy
Jack F.M. Wetzels, Nijmegen, The Netherlands
Personalized approach to IgA nephropathy, is supportive care the response for most patients?
Renato Monteiro, Paris, France
Personalized treatment in ANCA-associated vasculitis
Mårten Segelmark, Linköping, Sweden
Hematuria in glomerular disease - is it important for the outcome of the patients?
Jesus Egido, Madrid, Spain

- See more at: http://www.era-edta2017.org/en-US/preliminary-scientific-programme-1#sthash.S273ZyBf.dpuf
News in the pathogenesis and treatment of glomerular disease
IWG (Immunonephrology Working Group)
IWG

Part I - Complement mediated diseases: pathogenesis, new entities, upcoming treatments, how to handle expensive drugs
Complement activation in immune-mediated glomerular disease
Mohamed R. Daha, Leiden, The Netherlands
Complement staining in kidney biopsy (C3, C4, C5b-9)
Pablo Cannata-Ortiz, Madrid, Spain
Complement in ANCA-associated Vasculitis - new therapeutic target?
Annette Bruchfeld, Stockholm, Sweden
Complement activation in IgA nephropathy, membranous nephropathy and FSGS
Yasar Caliskan, Istanbul, Turkey
Targeting complement in atypical hemolytic uremic syndrome and C3 glomerulopathy
Giuseppe Remuzzi, Bergamo, Italy

Part II - Individualized (personalized) treatment of glomerular disease – is it already possible?
Personalized immunomonitoring and treatment in lupus nephritis
Hans-Joachim Anders, Munich, Germany
Personalized monitoring and treatment in membranous nephropathy
Jack F.M. Wetzels, Nijmegen, The Netherlands
Personalized approach to IgA nephropathy, is supportive care the response for most patients?
Renato Monteiro, Paris, France
Personalized treatment in ANCA-associated vasculitis
Mårten Segelmark, Linköping, Sweden
Hematuria in glomerular disease - is it important for the outcome of the patients?
Jesus Egido, Madrid, Spain

- See more at: http://www.era-edta2017.org/en-US/preliminary-scientific-programme-1#sthash.S273ZyBf.dpuf

Athens Winter School in Nephrology – Focus in Glomerular Diseases
FEBRUARY 27-29, 2020 – ATHENS, GREECE
Join the Athens Winter meeting 2020, an educational event organised by the Immunonephrology Working Group (IWG) of the ERA EDTA and Mayo Clinic (Rochester USA) in collaboration with Hellenic Society of Nephrology. The meeting is mainly focused on glomerular diseases but also covers a wide spectrum of topics in the field of nephrology such as kidney transplantation, chronic kidney diseases and the relation between pregnancy and the kidneys.
Read more

 

 


4th International Renal Pathology Conference

APRIL 16 – 18, 2020 - WARSAW, POLAND

Join one of the most important meetings dedicated to native and transplant kidney diseases.
The Conference is a joint meeting of the Renal Pathology Society, The Department of Transplantation, Nephrology
and Internal Medicine, Medical University of Warsaw and the Nephropathology Working Group of the European
Society of Pathology.
Read more



20th International Vasculitis and ANCA Workshop

April 18-21 2021 - DUBLIN, IRELAND

The conference theme will be “Autoimmunity, Autoinflammation and Immunodeficiency in Vasculitis”. The programme focused on basic science and clinical research, communicating new knowledge, and advocating for the highest quality care for patients with vasculitis.

CALL FOR ABSTRACTS: September 15, 2020

Read more